Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaratumab in metastatic castration-refractory prostate cancer
NCT01204710Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2010
- Primary completion
- Sep 2012
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of olaratumab in prostate cancer (PCa), sponsored by Eli Lilly and Company. Started Oct 2010; status: completed.
02
Drugs
olaratumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01204710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01204710.